Research Article

Long-term Coexistence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) with Antibody Response in Coronavirus Disease 2019 (COVID-19) Patients

Bin Wang [#,1], Li Wang[#,1], Xianggen Kong[1], Jin Geng[1], Di Xiao[1], Chunhong Ma[2] , Xue-Mei Jiang[1,*] & Pei-Hui Wang[2, *]

[1.]Jinan Infectious Diseases Hospital of Shandong University, Jinan, Shandong 250021, China
[2] Advanced Medical Research Institute, Shandong University, Jinan, Shandong 250012, China

[#]These authors contributed equally to this work
[*]To whom correspondence should be addressed: Xue-Mei Jiang, shdjxm@163.com; Pei-Hui Wang, wphlab@163.com

Abstract

Severe acute respiratory syndrome coronavirus 2 infection causing coronavirus

disease 2019 has spread worldwide. Whether antibodies are important for the adaptive

immune responses against SARS-CoV-2 infection needs to be determined. Here, 26

cases of COVID-19 in Jinan, China, were examined and shown to be mild or with

common clinical symptoms and no cases of severe symptoms were found among

these patients. A striking feature of some patients is that SARS-CoV-2 could exist in

patients who have virus-specific IgG antibodies for a very long period, with one case

for up to 36 days. One COVID-19 patient who did not produce any

SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness,

revealing that without antibody-mediated adaptive immunity, innate immunity may

still be powerful enough to eliminate SARS-CoV-2. Overall, this report may provide a

basis for further analysis of both innate and adaptive immunity in SARS-CoV-2

clearance, especially in non-severe cases. This study also has implications for

understanding the pathogenesis and treatment of SARS-CoV-2.

Keywords: SARS-CoV-2, COVID-19, adaptive immunity, innate immunity, IgG

antibody

36   The first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

37 outbreak was reported in December 2019, and the virus has rapidly spread worldwide

38 within 3 months (Wu et al., 2020; Zhou et al., 2020; Zhu et al., 2020). The importance

39 of innate and adaptive immunity in the defense against SARS-CoV-1 needs to be

40 urgently determined (Thevarajan et al., 2020). To fulfill the pressing need, we

41 examined antibody generation and virus clearance in 26 patients with SARS-CoV-2

42 caused coronavirus disease 2019 (COVID-19) in Jinan, China.

44   A total of 26 patients from 5 to 72 years old were determined to be SARS-CoV-2

45 RNA positive in sputum, stool, or nasopharyngeal swabs. The clinical characteristics

46 of the patients and chest CT scans were also examined. According to the "Fifth

47 Revised Trial Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment

48 Guidance"

49 (http://www.nhc.gov.cn/yzygj/s7652m/202002/41c3142b38b84ec4a748e60773cf9d4f

50 .shtml), all of them are non-severe COVID-19 patients (**Table 1**).

52   Immunoglobulin G (IgG) antibodies act as an indicator of recent and past

53 infection while IgM antibodies indicate current infection. SARS-CoV-2–bound IgG

54 antibodies were detected in the serum of patients. For patients 3, 7, 22 and 24 (**Table**

55 **1**), SARS-CoV-2 nucleic acid measurements has become negative before antibodies

56 were detected. Although IgG antibody testing was positive for the first trial in all 4

57 patients, we could not determine the exact role of IgG antibodies in SARS-CoV-2

clearance, because innate immunity is also sufficient to eliminate this virus (refer to

the case of patient 26). However, the results did reveals that the antibodies are

produced early and SARS-CoV-2 is cleared up, indicating that the immediate

production of antibodies may contribute to virus clearance.

Interestingly, we observed that specimens from patients 2, 13, and 16 who had

been confirmed to be IgG antibody positive still tested positive for SARS-CoV-2

nucleic acid for more than 30 days (**Table 1**), indicating that SARS-CoV-2 can coexist

with its specific antibodies in the human body for an unexpectedly long time (34-36

days). According to the data collected from patient 2, IgG antibodies can be produced

at least as early as the 7th day post illness. (**Table 1**). The average number of days for

SARS-CoV-2 bound IgG antibodies to be firstly detected in the 3 patients was 12.3;

thus, the early production of antibodies does not mean early elimination of this virus.

The production of specific antibodies is believed to be effective for virus clearance

(Jiang, 2020; Lu, 2020), but we could not reach such a conclusion from these cases.

We did not observe the a correlation between early adaptive immune responses and

better clinical outcomes. Perhaps the specificity and titer of antibodies are more

important. To our knowledge, to date, this is the longest period (34-36 days) to

observe the coexistence of SARS-CoV-2 with its specific antibodies in COVID-19

patients. How this virus can circulate in the presence of specific antibodies for such a

long time is an interesting question. Whether SARS-CoV-2 can act as HCV that have

developed strategies to subvert humoral immunity and persists in the body is worth

further investigation (Elsner et al., 2015; Fafi-Kremer et al., 2012; Takaya et al.,

2019).

These 3 patients were all 23-39 year-old adults, which may suggest that young

adult individuals do not have obvious advantages in the early production of antibodies

and the clearance of SARS-CoV-2 compared to older persons (patients 10 and 21).

We observed that patient 26, a 5-10 year-old female, was SARS-CoV-2 nucleic

acid positive in a stool sample after 46 days of illness but became nucleic acid testing

negative in specimens of sputum, stool, and nasopharyngeal swabs on day 47 post

illness (**Table 1**). No SARS-CoV-2–specific antibodies were detected in the patient's

serum until the latest sample collection day, which was the 66th day post illness.

Although we did not collect data about virus-specific cellular immunity, it is known

that cellular immunity is generated concomitantly with humoral immunity, so we

could preliminarily exclude the potential role of cellular immunity in SARS-CoV-2

elimination in this case. Thus, from the data on patient 26, we may conclude that

innate immunity, the first line of host defense, can play an essential role in

SARS-CoV-2 clearance; moreover, innate immunity alone might be enough to clear

the virus. This case may also indicate that some individuals may not generate specific

antibodies after infection with SARS-CoV-2; thus, only testing SARS-CoV-2–specific

antibodies is not a good standard to determine infection, but combination with the

nucleic acid testing method may improve the accuracy of SARS-CoV-2 detection.

Patient 25, another 5-10 year-old female, was found to be IgG antibody positive

on the 10th day post illness, and the patient turned SARS-CoV-2 nucleic acid negative

on 23rd day post illness (**Table 1**). We also observed that a 5-10 year-old female

patient (patient 7) produced IgG antibodies on the 14th day post illness, and this

patient turned SARS-CoV-2 nucleic acid negative on the 28th day post illness (**Table**

1). These 2 cases may reveal that children do not show any defects in antibody

production and SARS-CoV-2 elimination compared with adults.

Although a vaccine is believed to be the ultimate preventive measure against

SARS-CoV-2 spread, generating a broadly protective and universal vaccine can take a

long time (Lu, 2020). In this study, in the case of patient 26 (**Table 1**), we observed

that innate immunity alone may be enough to completely clear SARS-CoV-2 infection.

This is the first report that innate immunity plays such an essential role in the host

defense against SARS-CoV-2, which highlights the importance of innate immunity in

SARS-CoV-2 clearance. Further studies are required to determine which factors or

signaling pathways of innate immunity contribute to this process. Whether individuals

with such responses are still at risk for reinfection needs further exploration. Similar

to other RNA viruses, SARS-CoV-2 RNA should be detected by endosomal Toll-like

receptors (TLRs) and cytosolic RIG-I-like receptors or other RNA sensors that

activate NLRP3 signaling, leading to the production of IFNs, ISGs, and

proinflammatory cytokines (Kasumba and Grandvaux, 2019). Boosting innate

immune signaling pathways, such as TLR3 and RIG-I pathways, by drugs that mimic

viral RNA may contribute to SARS-CoV-2 clearance (Kasumba and Grandvaux,

2019). However, these immune stimulators also induce an inflammatory response that

may be harmful to patients, thus, antiviral immunity should be maximized, and

inflammatory responses must be minimized. The inflammatory response that is

responsible for the accumulation of cells and fluids contributes to SARS□induced

lung injury (Huang et al., 2020; Wang et al., 2020). As immune stimulators, viral

RNA mimics also induce an inflammatory response that may be harmful to patients;

thus a strategy in which antiviral immunity should be maximized and inflammatory

responses must be minimized, is challenging. Vaccine combined with innate immune

stimulators may be more effective for fast SARS-CoV-2 clearance. We propose that

the importance of innate immunity should be investigated further and that the titer and

specificity of SARS-CoV-2–specific antibodies are important and should be seriously

considered in vaccine development.

Our study is limited by the current reagents used in this study, which cannot be

used to determine the titer and specificity of human antibodies against SARS-CoV-2.

The titer of specific antibodies correlated with clinical outcomes remains to be

investigated. The long-term coexistence of IgG antibody with SARS-CoV-2 in the

human body raises the question of whether patients with antibodies are still at risk for

reinfection. Our follow-up studies may answer this question and would, therefore, be

beneficial to vaccine development. Second, we did not collect the earliest serum of

patients, and we could not determine on which day the SARS-CoV-2 bound IgG

antibodies generated. Thus, we could not observe the dynamic changes in IgG

antibodies during illness and recovery. Third, we lack severe patients as controls;

therefore, we do not know whether the adaptive immunity of severe patients can

respond earlier because of their strong immune response and whether they can clear

the virus faster after antibodies are produced. Despite that, our study provided several

novel pieces of information about the innate and adaptive immune response against

SARS-CoV-2: IgG antibodies can be generated as early as 7 days post illness but can

coexist with SARS-CoV-2 in patients long-term; without IgG antibodies, innate

immunity can also successfully clear SARS-CoV-2.

Materials and Methods

Specimens from sputum, stool, and nasopharyngeal swabs were collected

throughout the illness from January 30, 2020, to March 19, 2020. Viral RNA was

extracted from clinical specimens and real-time reverse transcription-PCR (rRT-PCR)

was performed to test the presence of SARS-CoV-2 using "Novel coronavirus

2019-nCoV nucleic acid detection kit" (Shanghai BioGerm Medical Biotechnology

Co.,Ltd, China). The serum was collected at distinctive time points, and

SARS-CoV-2–specific antibodies were detected using "New Coronavirus

(2019-nCoV) Antibody Detection Kit" (INNOVITA, China). This study was approved

by the ethics commissions of Jinan infectious disease hospital, Shandong, China.

Acknowledgement

This work was supported by grants from COVID-19 emergency tackling research

project of Shandong University (Grant No. 2020XGB03 to P.-H.W).

References

Elsner, R.A., Hastey, C.J., Olsen, K.J., and Baumgarth, N. (2015). Suppression of

Long-Lived Humoral Immunity Following Borrelia burgdorferi Infection. PLoS

Pathog *11*, e1004976.

Fafi-Kremer, S., Fauvelle, C., Felmlee, D.J., Zeisel, M.B., Lepiller, Q., Fofana, I.,

Heydmann, L., Stoll-Keller, F., and Baumert, T.F. (2012). Neutralizing antibodies

and pathogenesis of hepatitis C virus infection. Viruses *4*, 2016-2030.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu,

X., *et al.* (2020). Clinical features of patients infected with 2019 novel

coronavirus in Wuhan, China. Lancet *395*, 497-506.

Jiang, S. (2020). Don't rush to deploy COVID-19 vaccines and drugs without

sufficient safety guarantees. Nature *579*, 321.

Kasumba, D.M., and Grandvaux, N. (2019). Therapeutic Targeting of RIG-I and

MDA5 Might Not Lead to the Same Rome. Trends Pharmacol Sci *40*, 116-127.

Lu, S. (2020). Timely development of vaccines against SARS-CoV-2. Emerg

Microbes Infect *9*, 542-544.

Takaya, A., Yamamoto, T., and Tokoyoda, K. (2019). Humoral Immunity vs.

Salmonella. Front Immunol *10*, 3155.

Thevarajan, I., Nguyen, T.H.O., Koutsakos, M., Druce, J., Caly, L., van de Sandt, C.E.,

Jia, X., Nicholson, S., Catton, M., Cowie, B.*, et al.* (2020). Breadth of

concomitant immune responses prior to patient recovery: a case report of

non-severe COVID-19. Nature Medicine.

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z.,

Xiong, Y., *et al.* (2020). Clinical Characteristics of 138 Hospitalized Patients

With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA.

Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W., Tian,

J.H., Pei, Y.Y., *et al.* (2020). A new coronavirus associated with human

respiratory disease in China. Nature.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li,

B., Huang, C.L., *et al.* (2020). A pneumonia outbreak associated with a new

coronavirus of probable bat origin. Nature.

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W.,

Lu, R., *et al.* (2020). A Novel Coronavirus from Patients with Pneumonia in

China, 2019. N Engl J Med *382*, 727-733.

Table 1 Clinical characteristics of the 26 hospitalized SARS-CoV-2 patients and

corresponding timelines of IgG antibody production.

Patients	Gender/Age (Y.)	Type	IgG P. (D.)	LDVP/specimens	Co-existence (D.)
1	F/18-60	C	22	22/NP	0
2	M/18-60	C	7	42/SP	35
3	F/18-60	C	23	18/NP	NA
4	F/18-60	C	16	32/ST	16
5	F/18-60	C	23	29/NP	6
6	F/18-60	C	21	21/ST	0
7	F/18-60	M	9	8/NP	NA
8	M/18-60	C	23	43/NP	20
9	M/18-60	C	10	23/NP	13
10	M/>60	C	9	19/SP&NP	10
11	M/18-60	C	17	20/NP	3
12	F/<18	M	14	28/ST	14
13	M/18-60	C	15	51/ST	36
14	F/18-60	C	10	25/SP	24
15	M/18-60	C	24	36/NP	12
16	F/18-60	C	15	49/NP	34
17	M/18-60	C	20	36/SP	16
18	M/18-60	M	17	24/NP	7
19	M/18-60	C	12	21/SP	9
20	F/18-60	C	18	20/NP	2
21	F/>60	C	14	20/NP	6
22	M/18-60	M	10	7/NP	NA
23	F/18-60	C	15	18/NP	3
24	F/18-60	C	18	17/NP	NA
25	F/<18	C	10	23/ST	13
26	F/<18	M	ND* (66th)	46/ST	NA

211
Y: year; **IgG P**: IgG positive; **LDVP**: Last day post-illness when SARS-CoV-2
nucleic acid testing shows positive; **NP**: nasopharyngeal; **SP**: sputum; **ST**: stool. The
severity of COVID-19 was judged according to the "Fifth Revised Trial Version of the
Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance". **M**: mild type,
the clinical symptoms were mild and no pneumonia was found in imaging. **C**:
common type, with fever, respiratory tract and other symptoms, the manifestations of
pneumonia can be seen on imaging. **NA**: not applicable; **ND**: not detectable. * IgG
antibodies keep undetectable till 66th day post-illness for patient 26.
220